



PTO/SB/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

10/700,599

Filing Date

November 4, 2003

First Named Inventor

Bohrmann et al.

Art Unit

Examiner Name

Attorney Docket Number

21459 US

ENCLOSURES (Check all that apply)

- | | | |
|------------------------------------------------------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> After Allowance Communication to Group |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment/Reply | <input type="checkbox"/> Petition | <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declaration(s) | <input type="checkbox"/> Power of Attorney, Revocation | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | |
| <input checked="" type="checkbox"/> Information Disclosure Statement | <input type="checkbox"/> Request for Refund | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| <input type="checkbox"/> Response to Missing Parts/Incomplete Application | | |
| <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | | |

Remarks

-References B1 and C1 to C18.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual

Kimberly J. Prior

Signature

Date

February 5, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date February 5, 2004

Typed or printed

Kimberly J. Prior

Signature

Date

February 5, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors: Bohrmann, et al.

Serial No. 10/700,599, filed November 4, 2003
(Ref. No. 21459 US)

For: **QUANTIFICATION OF BETA AMYLOID**

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
February 5, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.


Documents B1 and C1 to C18, listed on Form PTO-1449 are enclosed.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/700,599
Filed: November 4, 2003


Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application no fee is due.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Kimberly J. Prior", written over a horizontal line.

Attorney for Applicant(s)
Kimberly J. Prior
(Reg. No. 41,483)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-6208
Telefax: (973) 235-2363

138743



Substitute for form 1449A/PTO				Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/700,599		
				Filing Date	November 4, 2003		
				First Name Inventor	Bohrmann, et al.		
(Use several sheets if necessary)				Attorney Docket Number	21459 US		
Sheet	1	of	2				
U.S. PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
	A						
FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	B1	EP 0 641 861			F.Hoffmann-La Roche AG	03/08/1995	
NON PATENT LITERATURE DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					T ²
	C1	Schutze et al. (1998) Identification of expressed genes by laser-mediated manipulation of single cells, Nature Biotechnology 16:737-742					
	C2	Simone et al. (1998) Laser-capture microdissection: opening the microscopic frontier to molecular analysis, TIG 14:272-276					
	C3	Teller, J. K. et al., Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome Nat. Med. 1996, 2, 93-95					
	C4	Kuo, Y. M. et al., Water-soluble ABeta (N-40, N42) oligomers in Normal and Alzheimer Disease Brains, J. Biol. Chem. 1996, 271, 4077-4081					
	C5	J. Naslund, A. Schierhorn, U. Hellman, L. Lannfelt, AD Roses, LO Tjernberg, J. Silberring, SE Gandy, B. Winblad, PG gard, C. Nordstedt, and L. Terenius (1994) Relative Abundance of Alzheimer ABeta Amyloid Peptide Variants in Alzheimer Disease and Normal Aging, PNAS 91:8378-8382					
	C6	Burdick, D. et al., Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs, J. Biol. Chem. 1992, 267, 546-554					
	C7	Barrow, C. J. et al., Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra, J. Mol. Biol. 1992, 225, 1075-1093					
Examiner Signature		Date Considered					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/700,599
				Filing Date	November 4, 2003
				First Name Inventor	Bohrmann, et al.
(Use several sheets if necessary)					
Sheet	2	of	2	Attorney Docket Number	21459 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C8	J. Stults et al., Simplification of High-Energy Collision Spectra of Peptides by Amino-Terminal Derivatization, Anal. Chem. 1993, 65, 1703-1708	
	C9	B. Spengler et al., Peptide sequencing of charged derivatives by postsource decay MALDI mass spectrometry, Int. J. Mass Spectrom. 1997, 169-170, 127-140	
	C10	Z. Huang et al., Protein Sequencing by Matrix-Assisted Laser Desorption Ionization-Postsource Decay-Mass Spectrometry Analysis of the N-Tris (2,4,6-trimethoxyphenyl)phosphine-Acetylated Tryptic Digests*1, Anal. Biochem. 1999, 268, 305-317	
	C11	Staudenmann W. and James P. in Proteome Research: Mass Spectrometry (P. James, Ed) Springer Verlag, Berlin (2001) 143-166	
	C12	Richards J. G., Ozmen L., Brockhaus M., Bohrmann B., Malherbe P., Jacobsen, H., Huber G.S, Bluethmann H., Kew J.N.C., Kemp J.A. Ouagazzal A.M. and Higgins G.A., Double transgenic mice overexpressing hAPPswe and hPSmut show age-dependent cognitive deficits and amyloid deposits in discrete brain regions, Soc. Neurosci. Abstr. 2001, Vol. 27, Program No. 546.7	
	C13	Carter et al. (1998), A Model for Structure-Dependent Binding of Congo Red to Alzheimer Beta-Amyloid Fibrils, Neurobiology of Aging 19: 37-40	
	C14	Selkoe D.J. (2001) Alzheimer's Disease: Genes Proteins & Therapy, Physiological Reviews 81: 741-766	
	C15	Kirschner D.A. et al., J. Proc. Natl. Acad. Sci. USA 1987, Vol. 84, 6953-6957	
	C16	Srinivasan, R. (1986) Science 234:559-565	
	C17	Doebeli et al. (1995) Biotechnology 13:988-993	
	C18	Ida et al. (1996) J. Biol. Chem. 271:22908-22914	
Examiner Signature			DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or abstract is attached.